FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605232103> ?p ?o ?g. }

• W2605232103 endingPage "884" @default.
• W2605232103 startingPage "873" @default.
• W2605232103 abstract "Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, works intracellularly within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo-controlled study evaluated efficacy and safety of apremilast among Japanese patients with moderate to severe plaque psoriasis. In total, 254 patients were randomized to placebo, apremilast 20 mg b.i.d. (apremilast 20) or apremilast 30 mg b.i.d. (apremilast 30) through week 16; thereafter, all placebo patients were re-randomized to apremilast 20 or 30 through week 68. Efficacy assessments included achievement of 75% or more reduction from baseline in Psoriasis Area and Severity Index score (PASI-75; primary) and achievement of static Physician Global Assessment (sPGA; secondary) score of 0 (clear) or 1 (minimal) at week 16. Safety was assessed through week 68. At week 16, PASI-75 response rates were 7.1% (placebo), 23.5% (apremilast 20; P = 0.0032 vs placebo) and 28.2% (apremilast 30; P = 0.0003 vs placebo); sPGA response rates (score of 0 or 1) were 8.8% (placebo), 23.9% (apremilast 20; P = 0.0165 vs placebo) and 29.6% (apremilast 30; P = 0.0020 vs placebo). Responses were maintained with apremilast through week 68. Most common adverse events (AEs) with placebo, apremilast 20 and apremilast 30 (0-16 weeks) were nasopharyngitis (8.3%, 11.8%, 11.8%), diarrhea (1.2%, 8.2%, 9.4%), and abdominal discomfort (1.2%, 1.2%, 7.1%), respectively. Exposure-adjusted incidence of these AEs did not increase with continued apremilast treatment (up to 68 weeks). Apremilast demonstrated efficacy and safety in Japanese patients with moderate to severe plaque psoriasis through 68 weeks that was generally consistent with prior studies." @default.
• W2605232103 created "2017-04-14" @default.
• W2605232103 creator A5003521431 @default.
• W2605232103 creator A5003710463 @default.
• W2605232103 creator A5013454968 @default.
• W2605232103 creator A5027905748 @default.
• W2605232103 creator A5056853483 @default.
• W2605232103 creator A5067909005 @default.
• W2605232103 creator A5068267699 @default.
• W2605232103 creator A5068867870 @default.
• W2605232103 creator A5080374235 @default.
• W2605232103 date "2017-04-09" @default.
• W2605232103 modified "2023-10-12" @default.
• W2605232103 title "Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial" @default.
• W2605232103 cites W1604295258 @default.
• W2605232103 cites W1919283206 @default.
• W2605232103 cites W1965032245 @default.
• W2605232103 cites W1996677952 @default.
• W2605232103 cites W2021018799 @default.
• W2605232103 cites W2027145044 @default.
• W2605232103 cites W2030298480 @default.
• W2605232103 cites W2058562555 @default.
• W2605232103 cites W2064709295 @default.
• W2605232103 cites W2067327580 @default.
• W2605232103 cites W2076204287 @default.
• W2605232103 cites W2076977862 @default.
• W2605232103 cites W2087624875 @default.
• W2605232103 cites W2089467255 @default.
• W2605232103 cites W2091442391 @default.
• W2605232103 cites W2095297002 @default.
• W2605232103 cites W2096991001 @default.
• W2605232103 cites W2107432039 @default.
• W2605232103 cites W2131082989 @default.
• W2605232103 cites W2131727392 @default.
• W2605232103 cites W2133309045 @default.
• W2605232103 cites W2156148414 @default.
• W2605232103 cites W2160630176 @default.
• W2605232103 cites W2266045195 @default.
• W2605232103 doi "https://doi.org/10.1111/1346-8138.13829" @default.
• W2605232103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5573969" @default.
• W2605232103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28391657" @default.
• W2605232103 hasPublicationYear "2017" @default.
• W2605232103 type Work @default.
• W2605232103 sameAs 2605232103 @default.
• W2605232103 citedByCount "51" @default.
• W2605232103 countsByYear W26052321032017 @default.
• W2605232103 countsByYear W26052321032018 @default.
• W2605232103 countsByYear W26052321032019 @default.
• W2605232103 countsByYear W26052321032020 @default.
• W2605232103 countsByYear W26052321032021 @default.
• W2605232103 countsByYear W26052321032022 @default.
• W2605232103 countsByYear W26052321032023 @default.
• W2605232103 crossrefType "journal-article" @default.
• W2605232103 hasAuthorship W2605232103A5003521431 @default.
• W2605232103 hasAuthorship W2605232103A5003710463 @default.
• W2605232103 hasAuthorship W2605232103A5013454968 @default.
• W2605232103 hasAuthorship W2605232103A5027905748 @default.
• W2605232103 hasAuthorship W2605232103A5056853483 @default.
• W2605232103 hasAuthorship W2605232103A5067909005 @default.
• W2605232103 hasAuthorship W2605232103A5068267699 @default.
• W2605232103 hasAuthorship W2605232103A5068867870 @default.
• W2605232103 hasAuthorship W2605232103A5080374235 @default.
• W2605232103 hasBestOaLocation W26052321031 @default.
• W2605232103 hasConcept C126322002 @default.
• W2605232103 hasConcept C142724271 @default.
• W2605232103 hasConcept C16005928 @default.
• W2605232103 hasConcept C168563851 @default.
• W2605232103 hasConcept C197934379 @default.
• W2605232103 hasConcept C204787440 @default.
• W2605232103 hasConcept C27081682 @default.
• W2605232103 hasConcept C2776260265 @default.
• W2605232103 hasConcept C2778375690 @default.
• W2605232103 hasConcept C2780564577 @default.
• W2605232103 hasConcept C2781427535 @default.
• W2605232103 hasConcept C71924100 @default.
• W2605232103 hasConcept C90924648 @default.
• W2605232103 hasConceptScore W2605232103C126322002 @default.
• W2605232103 hasConceptScore W2605232103C142724271 @default.
• W2605232103 hasConceptScore W2605232103C16005928 @default.
• W2605232103 hasConceptScore W2605232103C168563851 @default.
• W2605232103 hasConceptScore W2605232103C197934379 @default.
• W2605232103 hasConceptScore W2605232103C204787440 @default.
• W2605232103 hasConceptScore W2605232103C27081682 @default.
• W2605232103 hasConceptScore W2605232103C2776260265 @default.
• W2605232103 hasConceptScore W2605232103C2778375690 @default.
• W2605232103 hasConceptScore W2605232103C2780564577 @default.
• W2605232103 hasConceptScore W2605232103C2781427535 @default.
• W2605232103 hasConceptScore W2605232103C71924100 @default.
• W2605232103 hasConceptScore W2605232103C90924648 @default.
• W2605232103 hasFunder F4320309086 @default.
• W2605232103 hasIssue "8" @default.
• W2605232103 hasLocation W26052321031 @default.
• W2605232103 hasLocation W26052321032 @default.
• W2605232103 hasLocation W26052321033 @default.
• W2605232103 hasLocation W26052321034 @default.
• W2605232103 hasOpenAccess W2605232103 @default.
• W2605232103 hasPrimaryLocation W26052321031 @default.
• W2605232103 hasRelatedWork W2034115370 @default.

• next